Loading...
Evotec SE
0IRF.IL•IOB
HealthcareDrug Manufacturers - Specialty & Generic
£6.98
£0.02(0.29%)
Evotec SE (0IRF.IL) Financial Performance & Statements
Review Evotec SE’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
1.99%
↑ 1.99%
Operating Income Growth
-200.00%
↓ 200.002%
Net Income Growth
-133.67%
↓ 133.67%
Operating Cash Flow Growth
-50.00%
↓ 50.00%
Operating Margin
-18.31%
↓ 18.31%
Gross Margin
13.62%
↑ 13.62%
Net Profit Margin
-26.26%
↓ 26.26%
ROE
-21.53%
↓ 21.53%
ROIC
-9.09%
↓ 9.09%
Evotec SE (0IRF.IL) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Evotec SE stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $221.23M | $184.89M | $182.12M | $208.73M |
| Cost of Revenue | $175.13M | $166.61M | $166.38M | $173.97M |
| Gross Profit | $46.10M | $18.28M | $15.74M | $34.76M |
| Gross Profit Ratio | $0.21 | $0.10 | $0.09 | $0.17 |
| R&D Expenses | $9.73M | $11.87M | $13.01M | $16.24M |
| SG&A Expenses | $49.90M | $46.39M | $45.97M | $45.94M |
| Operating Expenses | $39.31M | $44.78M | $58.98M | $62.18M |
| Total Costs & Expenses | $214.44M | $211.38M | $225.36M | $236.15M |
| Interest Income | -$367000.00 | $917000.00 | $467000.00 | $1.42M |
| Interest Expense | $4.42M | $1.87M | $2.74M | $2.67M |
| Depreciation & Amortization | $0.00 | $0.00 | $1.45M | $17.77M |
| EBITDA | -$11.45M | -$45.008M | -$103.17M | -$15.95M |
| EBITDA Ratio | -$0.05 | -$0.24 | -$0.57 | -$0.08 |
| Operating Income | $6.78M | -$26.49M | -$104.61M | -$27.42M |
| Operating Income Ratio | $0.03 | -$0.14 | -$0.57 | -$0.13 |
| Other Income/Expenses (Net) | -$22.65M | -$20.38M | $151000.00 | $638000.00 |
| Income Before Tax | -$15.87M | -$46.87M | -$104.45M | -$25.73M |
| Income Before Tax Ratio | -$0.07 | -$0.25 | -$0.57 | -$0.12 |
| Income Tax Expense | $24.97M | -$7.24M | -$9.52M | -$6.11M |
| Net Income | -$40.84M | -$39.63M | -$94.93M | -$20.67M |
| Net Income Ratio | -$0.18 | -$0.21 | -$0.52 | -$0.10 |
| EPS | -$0.23 | -$0.22 | -$0.54 | -$0.12 |
| Diluted EPS | -$0.23 | -$0.22 | -$0.54 | -$0.12 |
| Weighted Avg Shares Outstanding | $177.30M | $177.35M | $177.30M | $177.30M |
| Weighted Avg Shares Outstanding (Diluted) | $177.30M | $177.35M | $177.30M | $177.30M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan